Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Schinus molle pollen is an allergenic extract derived from the pollen of the Peruvian peppertree (Schinus molle). [8] It is a biologic product used for both diagnosing and treating allergies to this specific pollen. For diagnosis, it is administered via percutaneous (prick) or intradermal skin tests to identify sensitization. For treatment, it is used in subcutaneous immunotherapy, a process that involves administering gradually increasing doses of the allergen to help the immune system build tolerance and reduce the severity of allergic symptoms upon natural exposure. The extract was first approved in the United States in 1941.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on schinus molle pollen.